| Literature DB >> 29516014 |
Lisa Repsold1, Anna Margaretha Joubert1.
Abstract
Erythrocytes play an important role in oxygen and carbon dioxide transport. Although erythrocytes possess no nucleus or mitochondria, they fulfil several metabolic activities namely, the Embden-Meyerhof pathway, as well as the hexose monophosphate shunt. Metabolic processes within the erythrocyte contribute to the morphology/shape of the cell and important constituents are being kept in an active, reduced form. Erythrocytes undergo a form of suicidal cell death called eryptosis. Eryptosis results from a wide variety of contributors including hyperosmolarity, oxidative stress, and exposure to xenobiotics. Eryptosis occurs before the erythrocyte has had a chance to be naturally removed from the circulation after its 120-day lifespan and is characterised by the presence of membrane blebbing, cell shrinkage, and phosphatidylserine exposure that correspond to nucleated cell apoptotic characteristics. After eryptosis is triggered there is an increase in cytosolic calcium (Ca2+) ion levels. This increase causes activation of Ca2+-sensitive potassium (K+) channels which leads to a decrease in intracellular potassium chloride (KCl) and shrinkage of the erythrocyte. Ceramide, produced by sphingomyelinase from the cell membrane's sphingomyelin, contributes to the occurrence of eryptosis. Eryptosis ensures healthy erythrocyte quantity in circulation whereas excessive eryptosis may set an environment for the clinical presence of pathophysiological conditions including anaemia.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29516014 PMCID: PMC5817309 DOI: 10.1155/2018/9405617
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Diagram illustrating eryptosis signalling. Injury to erythrocytes activates the release of prostaglandin E2 (PGE2), which, in turn, activates the Ca2+ cation channels increasing the influx of Ca2+ ions into the erythrocyte and activating Ca2+-sensitive scramblase. The latter causes exposure of phosphatidylserine on the cell membrane. All this leads to the formation of the characteristics of eryptosis including membrane blebbing and cell shrinkage. NO: nitric oxide, PAF: platelet activating factor, ROS: reactive oxygen species, COX: cyclooxygenase, PLA: phospholipase A2, SCR: scramblase, and PGE2: prostaglandin E2 [adapted from [11]].
Factors that stimulate eryptosis. Activation mechanisms can occur through Ca2+ ion entry, ceramide formation, or adenosine triphosphate (ATP) depletion.
| Stimulating factors | Activation mechanism | References |
|---|---|---|
| Aluminium | Ca2+ | [ |
| Amantadine | Ca2+ | [ |
| Amiodarone | Ca2+ | [ |
| Amphotericin B | Ca2+; ATP depletion | [ |
| Amyloid | Ceramide | [ |
| Anandamide | Ca2+ | [ |
| Anti-A IgG | Ca2+ | [ |
| Arsenic | Ca2+; ceramide; ATP depletion | [ |
| Azathioprine | Ca2+ | [ |
| Bismuth chloride | Ca2+; ceramide | [ |
| Cadmium | Ca2+; ATP depletion | [ |
| Chlorpromazine | Ca2+ | [ |
| Ciglitazone | Ca2+ | [ |
| Cisplatin | Ca2+ | [ |
| Copper | Ceramide | [ |
| Cordycepin | Ca2+ | [ |
| Cryptotanshinone | Ca2+ | [ |
| Curcurmin | Ca2+; ceramide | [ |
| Cyclosporine | Ceramide; ATP depletion | [ |
| CD95/Fas/ligand | ATP depletion | [ |
| Glycophorin-C | ATP depletion | [ |
| Gold chloride | Ca2+ | [ |
| Hemin | Ca2+; ceramide | [ |
| Hemolysin | Ca2+ | [ |
| Lead | Ca2+ | [ |
| Leukotriene C | Ca2+ | [ |
| Lipopeptides | ATP depletion | [ |
| Listeriolysin | Ca2+; ATP depletion | [ |
| Lithium | Ca2+ | [ |
| Mercury | Ceramide; ATP depletion | [ |
| Methyldopa | Ceramide; ATP depletion | [ |
| Methylglyoxal | Ceramide | [ |
| Paclitaxel | Ca2+; ceramide | [ |
| PAF | Ceramide | [ |
| Peptidoglycan | Ca2+; ceramide | [ |
| Radiocontrast agents | Ca2+; ATP depletion | [ |
| Retinoic acid | Ca2+ | [ |
| Selenium | Ca2+; ceramide | [ |
| Silver ions | ATP depletion | [ |
| Thrombospondin-1-receptor CD47 | ATP depletion | [ |
| Thymoquinone | ATP depletion | [ |
| Tin | Ca2+; ceramide; ATP depletion | [ |
| Valinomycin | ATP depletion | [ |
| Vanadate | Ca2+ | [ |
| Vitamin K (3) | Ceramide | [ |
| Zinc | Ca2+; ceramide | [ |
Factors inhibiting eryptosis. Inhibition mechanism can be through the Ca2+ entry mechanism, ceramide formation, or ATP depletion.
| Inhibiting factors | Inhibition mechanism | References |
|---|---|---|
| Adenosine | Ca2+; ATP depletion | [ |
| Amitriptyline | Ceramide; ATP depletion | [ |
| Caffeine | Ca2+; ATP depletion | [ |
| Catecholamine's | Ca2+ | [ |
| Chloride | Ca2+ | [ |
| Ethylisopropylamiloride | Ca2+ | [ |
| Erythropoietin | Ca2+ | [ |
| Flufenamic acid | Ca2+ | [ |
| Quinoxalinediones (NBQX/CNQX) | Ca2+ | [ |
| Niflumic acid | ATP depletion | [ |
| Nitric oxide (nitroprusside) | ATP depletion | [ |
| Natriuretic peptide precursor B | ATP depletion | [ |
| Resveratrol | Ca2+; ATP depletion | [ |
| Staurosporine | ATP depletion | [ |
| Urea | Ceramide; ATP depletion | [ |
| Xanthohumol | Ca2+; ATP depletion | [ |
| Zidovudine | Ca2+ | [ |
Diseases resulting in accelerated eryptosis. Activation mechanisms occur through Ca2+ ion entry, ceramide formation, and inhibition of ATP depletion.
| Disease | Activation mechanism | References |
|---|---|---|
| Iron deficiency | Ca2+ | [ |
| Phosphate depletion | ATP depletion | [ |
| Neocytolysis | ATP depletion | [ |
| Sepsis | Ceramide formation | [ |
| Haemolytic anaemia | Ca2+; ceramide formation; ATP depletion | [ |
| Haemolytic uremic syndrome | Ca2+; ceramide formation | [ |
| Renal Insufficiency | Ca2+ | [ |
| Malaria | Ca2+ | [ |
| Sickle cell disease | ATP depletion | [ |
| Thalassemia | ATP depletion | [ |
| Glucose-6-phosphate dehydrogenase deficiency | ATP depletion | [ |
| Wilson's disease | Ceramide formation | [ |
| Anion exchanger 1 mutation | Ca2+ | [ |
| Glucose transporter 1 mutation | Ca2+ | [ |